

This is only an advertisement for information purpose and not an offer document announcement. Not for publication, distribution or release directly or indirectly into the United States of America or otherwise outside India. All capitalized terms used and not defined herewith shall have the same meaning assigned to them in the Letter of Offer dated July 7, 2023 (the "Letter of Offer" or "LOF") filed with the Stock Exchange, namely BSE Limited ("BSE") (together referred to as the "Stock Exchange") and the Securities and Exchange Board of India ("SEBI").



## EIKO LIFESCIENCES LIMITED

Eiko Lifesciences Limited ("Company" or "Issuer") was originally incorporated as "Narendra Investments (Delhi) Private Limited" at Delhi, under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated January 07, 1977, issued by Registrar of Companies, Delhi & Haryana. The name of the Company has been changed from Narendra Investments (Delhi) Private Limited to Narendra Investments (Delhi) Limited pursuant to conversion under Registrar of Companies, Delhi & Haryana on March 05, 1982. The Company having by special resolution dated April 09, 2014, altered the provisions of Memorandum of Association with respect to the place of the Registered Office by changing it from the state of Delhi to the Maharashtra as confirmed by an order of Regional Director bearing the date August 19, 2014, vide certificate of registration of Regional Director order for change of state as certified dated September 16, 2014. The name of the Company has been changed from Narendra Investments (Delhi) Limited to Eiko Lifesciences Limited with effect from June 24, 2021, by the Registrar of Companies, Mumbai, Maharashtra. The Corporate Identification Number of our Company is L65993MH1977PLC258134. For further details about the Company, please refer to the section titled "General Information" beginning on page 30 of the Letter of offer.

Registered Office: 604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate, Thane-400604, Maharashtra, India  
Tel: +91 22 25438095; Email: investor\_relations@eikolifesciences.com; Website: www.eikolifesciences.com  
Contact Person: Mr. Jaid Ismail Kojar, CFO

PROMOTERS OF THE COMPANY: MR. LAXMIKANT RAMPRASAD KABRA AND MR. BHAVESH DHIRAJAL TANNA

ISSUE OF UPTO 55,44,178 EQUITY SHARES OF FACE VALUE OF ₹10 EACH ("EQUITY SHARES") OF EIKO LIFESCIENCES LIMITED ("EIKO" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF RS. 45 PER EQUITY SHARE (INCLUDING PREMIUM OF RS. 35 PER EQUITY SHARE) ("ISSUE PRICE") FOR AN AGGREGATE AMOUNT NOT EXCEEDING ₹2,494.88\* LACS TO THE ELIGIBLE EQUITY SHAREHOLDERS ON RIGHTS BASIS IN THE RATIO OF 2 (TWO) EQUITY SHARE FOR EVERY 3 (THREE) EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, I.E. FRIDAY JULY 07, 2023 (THE "ISSUE"). THE ISSUE PRICE IS 4.5 TIMES OF FACE VALUE OF THE EQUITY SHARES. FOR FURTHER DETAILS, PLEASE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 112 OF THE LETTER OF OFFER

### BASIS OF ALLOTMENT

The Board of Directors of Eiko Lifesciences Limited thanked all its Equity Shareholders, members and investors for the response to the Company's Rights Issue of Equity Shares which opened for subscription on Monday, July 17, 2023, and closed on Saturday, July 26, 2023 and the last date for on-market renunciation of Rights Entitlements was Thursday, July 20, 2023. Out of the total 1569 Applications for 1,09,82,800 Equity Shares through the Application Supported by Blocked Amount ("ASBA"), 446 Applications for 7,84,412 Equity Shares were rejected due to technical reasons as disclosed in the LOF. The total number of valid applications received were 1569 for 1,09,82,800 Equity Shares, which aggregates to 198.10% of the total number of Equity Shares allotted under the Issue. In accordance with the LOF and the basis of allotment finalized on August 02, 2023, in consultation with the Lead Manager, the Registrar to the Issue and BSE Limited, the Designated Stock Exchange for the Issue, the Company has on August 02, 2023, allotted 55,44,178 Equity Shares to the successful applicants. We hereby confirm that all the valid applications have been duly considered for Allotment.

#### 1. Information regarding total number of Applications received:

Category	Total number of Applications received			Equity Shares applied for			Equity Shares allotted		
	Number	%	Value (₹)	Number	Value (₹)	%	Number	Value (₹)	%
Eligible Equity Shareholders	1499	95.54	1,02,95,758	13,89,92,733	93.74	50,87,364	6,86,79,414	91.76	
Renounees	70	4.46	6,87,042	92,75,067	6.26	4,56,814	61,66,989	8.24	
<b>Total</b>	<b>1569</b>	<b>100.00</b>	<b>1,09,82,800</b>	<b>28,65,64,860</b>	<b>100.00</b>	<b>55,44,178</b>	<b>7,48,46,403</b>	<b>100.00</b>	

#### 2. Basis of Allotment

Category	Number of valid Application received and considered for allotment	Number of Equity Shares accepted and allotted against Rights Entitlements (A)	Number of Equity Shares accepted and allotted against additional Equity Shares applied for (B)	Total Equity Shares accepted and allotted (A+B)
Eligible Equity Shareholders	1053	46,30,517	4,56,847	50,87,364
Renounees	70	4,56,814	0	4,56,814
<b>Total</b>	<b>1123</b>	<b>50,87,331</b>	<b>4,56,847</b>	<b>55,44,178</b>

**Intimations for Allotment / refund/ rejection cases:** The dispatch of allotment advice cum refund intimation and question for rejection, as applicable, to the Investors has been completed on August 03, 2023. The instructions to Self-Certified Syndicate Banks ("SCSBs") for unblocking funds in case of ASBA Applications were given on August 02, 2023. The Listing application was executed with BSE on August 4, 2023. The credit of Equity Shares in dematerialized form to respective demat accounts of allottees has been completed on August 08, 2023. No physical shares were rendered in the Rights Issue. Pursuant to the listing and trading approvals granted to be granted by BSE, the Rights Equity Shares Allotted in the issue is expected to commence trading on BSE on or about August 11, 2023. In accordance with the SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIRP/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has been sent to NSDL & CDSL on August 6, 2023.

**INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGE ONLY IN DEMATERIALIZED FORM**

**DISCLAIMER CLAUSE OF BSE:** It is to be distinctly understood that the permission given by BSE Limited should not in any way be deemed or construed that the Letter of Offer has been cleared or approved by BSE Limited, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of BSE" on page 107 of the Letter of Offer.

LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY
 <b>PNB INVESTMENT SERVICES LIMITED</b> PNB Pragati Towers, 2nd Floor, Plot No. C-9, G-Block, BKC, Bandra (E), Mumbai - 400 051, Maharashtra, India Telephone: +91 22 2672 6259 Contact Person: Ms. Menka Jha/ Mr. Sukant Goel E-mail: menka@pnbis.com/sukant@pnbis.com Website: www.pnbis.com Investor grievance: complaints@pnbis.com SEBI Registration Number: INM000011617	 <b>BIGSHARE SERVICES PRIVATE LIMITED</b> Office No S6-2, 6th Floor Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai - 400093, Maharashtra, India. Tel: 022 - 6263 8200/22 Contact Person: Mr. Vijay Surana Email: rightsisue@bigshareonline.com Website: www.bigshareonline.com Investors Grievance E-mail: investor@bigshareonline.com SEBI Registration Number: INF000001385	 <b>EIKO LIFESCIENCES LIMITED</b> 604, Centrum, Opp. TMC Office Near Satkar Grande Hotel, Wagle Estate, Thane-400604, Maharashtra, India Telephone: +91 22 25438095 Email: investor_relations@eikolifesciences.com Website: www.eikolifesciences.com Contact Person: Mr. Jaid Ismail Kojar, Chief Financial Officer Corporate Identification Number: L65993MH1977PLC258134

Investors may contact the Registrar to the Issue /Compliance Officer in case of any Pre-Issue/ Post Issue related problems such as non-receipt of Allotment advice/demat credit etc.

Investors may contact the Registrar or the Chief Financial Officer for any pre issue or post issue related matter. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSBs, giving full details such as name, address of the Applicant contact numbers, e-mail address of the sole/firsh holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked, ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as-the-case may be, was submitted by the Investors along with a photocopy of the acknowledgment slip.

**THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.**

For Eiko Lifesciences Limited

Sd/-  
Mr. Jaid Ismail Kojar  
Chief Financial Officer

Date: August 09, 2023  
Place: Mumbai

The LOF is available on the website of the SEBI at [www.sebi.gov.in](http://www.sebi.gov.in), the stock exchange i.e. BSE Limited at [www.bseindia.com](http://www.bseindia.com), the Lead Manager at [www.pnbis.com](http://www.pnbis.com) and the website of the Registrar to the Issue at [www.bigshareonline.com](http://www.bigshareonline.com). Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please see the section entitled "Risk Factors" beginning on page 17 of the "LOF".

The Rights Entitlements and the Rights Equity Shares have not been, and will not be registered under the United States Securities Act of 1933, as amended (the "US Securities Act") or under any securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold, offered, sold, exercised, renounced, pledged, transferred or delivered directly or indirectly within the United States or to, or for the account or benefit of, U.S. Persons (as defined in Regulations except for these purposes. U.S. Persons include persons who would otherwise have been excluded from such term solely by virtue of Rule 902(K)(1)(VII)(B) or Rule 902(K)(2)(i), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. Accordingly, the Rights Entitlements and Rights Equity Shares were offered and sold (i) in offshore transactions outside the United States to non-U.S. Persons compliance with Regulations to existing shareholders located in jurisdictions where such offer and sale of the Rights Equity Shares is permitted under laws of such jurisdictions, and (ii) in the United States to U.S. Persons who are U.S. QIBs and are also Qualified Purchasers pursuant to applicable exemptions under the US Securities Act and the Investment Company Act. There will be no public offering in the United States. The Rights Equity Shares and Rights Entitlements are not transferable except in accordance with the restrictions.

## SIEMENS

### Extract of Consolidated unaudited financial results for the quarter and nine months ended 30 June 2023

(₹ in million)

No.	Particulars	Quarter ended		Nine months ended	
		30 June 2023 (Unaudited)	30 June 2022 (Unaudited)	30 June 2023 (Unaudited)	30 September 2022 (Audited)
1	Total revenue from operations	48,732	42,583	137,461	161,378
2	Net Profit for the period before tax from continuing operations	6,071	4,078	18,776	17,117
3	Net Profit for the period after tax from continuing operations	4,558	3,025	13,903	12,619
4	Net Profit / (loss) for the period before tax from discontinued operations	-	(24)	-	3,700
5	Net Profit / (loss) for the period after tax from discontinued operations	-	(18)	-	2,811
6	Net Profit for the period	4,558	3,007	13,903	15,430
7	Total Comprehensive Income for the period [Comprising of Profit for the period and Other comprehensive income (after tax)]	4,517	3,256	12,744	15,472
8	Equity Share Capital	712	712	712	712
9	Reserves (excluding revaluation reserve) as shown in the audited Balance sheet of the previous year				115,390
10	Earnings Per Share (EPS) of ₹ 2 each (in Rupees) *				
	- Basic and diluted EPS for continuing operations	12.80	8.49	39.05	35.44
	- Basic and diluted EPS for discontinued operations	-	(0.05)	-	7.89
	- Basic and diluted EPS from total operations	12.80	8.44	39.05	43.33
	* not annualised except year end EPS				

#### Notes:

1 The specified items of the standalone financial results of the Company for the quarter and nine months ended 30 June 2023 are given below:

(₹ in million)

Particulars	Quarter ended		Nine months ended	
	30 June 2023 (Unaudited)	30 June 2022 (Unaudited)	30 June 2023 (Unaudited)	30 September 2022 (Audited)
Total revenue from operations	44,731	39,148	125,836	148,315
Net Profit for the period before tax from continuing operations	5,641	3,980	18,334	16,802
Net Profit for the period after tax from continuing operations	4,237	2,955	13,773	12,497
Net Profit / (loss) for the period before tax from discontinued operations	-	(24)	-	3,700
Net Profit / (loss) for the period after tax from discontinued operations	-	(18)	-	2,811
Total Comprehensive Income for the period	4,196	3,186	12,614	15,367

2 The above is an extract of the detailed format of Quarterly and Nine monthly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Nine monthly Standalone and Consolidated financial results are available on the Stock Exchange websites ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)) and on the Company's website ([www.siemens.co.in](http://www.siemens.co.in)).

Place : Zug, Switzerland  
Date : 8 August 2023

For Siemens Limited

**Siemens Limited**  
Registered office: Birla Aurora, Level 21, Plot No. 1080, Dr. Annie Besant Road, Worli, Mumbai - 400030  
Corporate Identity Number: L28920MH1957PLC010839  
Tel.: +91 22 6251 7000; Fax: +91 22 2436 2404  
Email / Contact: Corporate-Secretariat.in@siemens.com / [www.siemens.co.in/contact](http://www.siemens.co.in/contact)  
Website: [www.siemens.co.in](http://www.siemens.co.in)

Sunil Mathur  
Managing Director and  
Chief Executive Officer




## ORIENT PAPER & INDUSTRIES LTD.

CIN: L21011OR1936PLC000117

[Regd. Office : Unit VIII, Plot 7, Bhoingar, Bhubaneswar - 751012 (Odisha)]  
Tel: (0674) 2396930, E-mail : [paper@opilbbsr.com](mailto:paper@opilbbsr.com)

### Statement of Unaudited Financial Results for the Quarter ended 30th June, 2023



(₹ In Lacs)

Sl. No.	Particulars	Quarter Ended			Year Ended
		30-06-2023 (Unaudited)	31-03-2023 (Audited)	30-06-2022 (Unaudited)	31-03-2023 (Audited)
1	Total income from operations	24,327.37	25,847.57	21,121.63	94,295.67
2	Profit Before Tax	4,983.58	7,174.23	343.11	14,765.73
3	Net Profit for the period	3,218.47	4,995.25	223.36	9,924.57
4	Other comprehensive income not to be reclassified to profit & loss in subsequent periods (net of tax)	8,374.28	(1,396.30)	(4,999.91)	(13,131.77)
5	Total comprehensive income / loss (3+4)	11,592.75	3,598.95	(4,776.55)	(3,207.20)
6	Paid-up equity share capital (face value per share : Re.1/-)	2,121.96	2,121.96	2,121.96	2,121.96
7	Other Equity				1,49,425.96
8	Earning per Equity Share of face value of Re.1/- each (Not annualised) Basic & Diluted	1.52	2.35	0.11	4.68

#### Notes:-

- The above financial results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meetings held on 9th August, 2023. These financial results have been subjected to limited review by the Company's Statutory Auditors, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The above is an extract of the detailed format of Unaudited Financial Results for the quarter ended 30th June, 2023 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange websites. ([www.bseindia.com](http://www.bseindia.com) / [www.nseindia.com](http://www.nseindia.com)) and Company's website ([www.orientpaperindia.com](http://www.orientpaperindia.com)).

By Order of the Board  
For ORIENT PAPER & INDUSTRIES LTD.  
Sd/-  
(Ashwin J. Laddha)  
Managing Director & CEO  
(DIN 09538310)

Place : New Delhi  
Date : 9th August, 2023



**MISHRA DHATU NIGAM LIMITED**  
(A Government of India Enterprise) (CIN:L14292TG1973GOI001660)  
Registered & Corporate Office: PO Kanchanbagh, Hyderabad-500058  
Phone: 040-24184515, Website: [www.midhani-india.in](http://www.midhani-india.in)

### EXTRACT OF FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30<sup>th</sup>, 2023

#### A. Standalone Results

(₹ in Lakhs except per share data)

Sl. No.	Particulars	Quarter ended		Year ended
		30.06.2023 (Unaudited)	30.06.2022 (Unaudited)	31.03.2023 (Audited)
1	Total Income from operations	18,771.82	11,492.57	87,194.14
2	Net Profit for the period (before tax, exceptional items and/or extraordinary items) †	2,673.12	2,340.42	21,654.92
3	Net Profit for the period before tax (after exceptional items and/or extra ordinary items) †	2,673.12	2,340.42	21,654.92
4	Net Profit for the period after tax (after exceptional items and/or extra ordinary items) †	1,854.38	1,770.09	15,587.61
5	Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income for the period (after tax)]	1,865.96	1,767.46	15,579.87
6	Paid-up equity share capital (Face value of ₹ 10/- each)	18,734.00	18,734.00	18,734.00
7	Reserves (Excluding Revaluation Reserve)	-	-	1,09,885.42
8	Networth	-	-	1,28,619.42
9	Debt Equity Ratio (Times)	0.33	0.25	0.30
10	Earnings per share (Basic & Diluted) in (₹) (not annualised)	0.99	0.94	8.32
11	Debt Service coverage Ratio (Times)	0.11	0.13	0.71
12	Interest Service Coverage Ratio (Times)	5.74	8.72	11.48

#### B. Consolidated Results

(₹ in Lakhs except per share data)

Sl. No.	Particulars	Quarter ended		Year ended
		30.06.2023 (Unaudited)	30.06.2022 (Unaudited)	31.03.2023 (Audited)
1	Total revenue from operations	18,771.82	11,492.57	87,194.14
2	Net Profit for the period (before tax, exceptional items and/or extra ordinary items) †	2,673.12	2,340.42	21,654.92
3	Share of Profit / (Loss) of Joint Venture	16.65	6.41	38.84
4	Net Profit for the period before tax (after exceptional items and/or extra ordinary items) †	2,689.77	2,346.83	21,693.76
5	Net Profit for the period after tax (after exceptional items and/or extra ordinary items) †	1,871.03	1,776.50	15,626.45
6	Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income for the period (after tax)]	1,882.61	1,773.87	15,618.71
7	Paid-up equity share capital (Face value of ₹ 10/- each)	18,734.00	18,734.00	18,734.00
8	Reserves (Excluding Revaluation Reserve)	-	-	1,09,805.60
9	Networth	-	-	1,28,539.60
10	Debt Equity Ratio (Times)	0.33	0.25	0.30
11	Earnings per share (Basic & Diluted) in (₹) (not annualised)	1.00	0.95	8.34
12	Debt Service coverage Ratio (Times)	0.11	0.13	0.72
13	Interest Service Coverage Ratio (Times)	5.76	8.73	11.49

#### Notes:

- The above is an extract of the detailed format of Quarterly and Annual Financial Results filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015. The full format of the Quarter ended 30<sup>th</sup> June, 2023 Financial Results are available on the Stock Exchange Websites ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)) and on Company's website ([www.midhani-india.in](http://www.midhani-india.in)).
- Consolidated financial results for the Quarter Ended 30<sup>th</sup> June, 2023 include results of Utkarsha Aluminium Dhatu Nigam Limited (JV Company) which have been consolidated under equity method (50% Shareholding).
- †Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS.
- The above statement of financial results were reviewed and recommended by Audit Committee and approved by the Board of Directors at the meeting held on 08<sup>th</sup> August, 2023.

For Mishra Dhatu Nigam Limited  
Sd/-  
Dr. Sanjay Kumar Jha  
Chairman & Managing Director  
DIN:07533036

Place: Hyderabad  
Date: 08.08.2023